Trial Profile
A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jul 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gefitinib (Primary) ; Pemetrexed (Primary)
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms AGAIN
- 06 Jun 2023 Status changed from active, no longer recruiting to completed according to results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 05 Jan 2021 Status changed from recruiting to active, no longer recruiting.